Across pivotal trials, the most common AEs associated with neoadjuvant anti-HER2 therapy were chemotherapy-related toxicities, predominantly alopecia, nausea, anemia and neutropenia, with grade 3 neutropenia frequently reported [12,15]. Here, ERBB2 is linked to anemia (phenotype).